Redox State, Mitochondrial Metabolism and Autophagy in Cancer and Its Modulation by Antitumor Agents and Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Autophagy".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 274

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biology, Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico
Interests: mitochondria; reactive oxygen species; antioxidants
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Facultad de Qímica, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
Interests: redox state; mitochondrial metabolism; immunotherapy; cancer

Special Issue Information

Dear Colleagues,

Several antitumoral treatments exert their function through changes in the redox state, mitochondrial metabolism, and autophagy process of the tumoral cells. Meanwhile, some types of cancer require certain reactive oxygen species (ROS) levels to grow and develop metastasis; other types of cancer need reduced ROS levels to induce metastasis. It should be noted that high ROS levels also induce cell death as ROS can overcome the cell tumor umbral of resistance to oxidative stress (OS). Thus, cancer progression may depend on ROS, but ROS overproduction could be a therapeutic target to induce cancer cell death. Moreover, OS can induce mitochondrial damage and its dysfunction and, consequently, cell death. Autophagy is a degradation process that can degrade these dysfunctional mitochondria to promote new mitochondria biogenesis; if this cellular mechanism is not functioning properly, the tumor decreases because of the accumulation of damaged organelles. Thus, redox state, mitochondrial dysfunction, and autophagy are key events for cancer and metastasis reduction, and the exploration of these processes is crucial for the induction of metastasis and cancer reduction. Moreover, the immune response of the cancer patient associated with the latter processes plays a fundamental role in cancer elimination. Reviews and original research manuscripts that explore the effects of ROS, OS, autophagy, and immune response related to cancer development and its elimination, including antitumor agents and immunotherapy, are welcome to this Special Issue.

Prof. Dr. José Pedraza Chaverri
Guest Editor

Dr. Alfredo Cruz-Gregorio
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop